Drugs / HW071021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06882135 | May 2025 → Sep 2026 overdue | cancer | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HW071021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06882135 ↗ |
| Route | Oral | “Administered orally at pre-specified doses once or twice daily.” NCT06882135 ↗ |